Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shionogi & Co ( (JP:4507) ) just unveiled an update.
Shionogi & Co., Ltd. reported its financial results for the second quarter of FY 2025, showing a slight decrease in revenue by 0.5% to 213 billion yen. The company experienced a decline in prescription drug sales, particularly in the acute respiratory virus infection treatment segment, which saw a 65.1% drop. However, this was partially offset by an increase in royalty income, which rose by 6.4%. The company also noted an increase in sales-related expenses in the U.S. and costs associated with making Torii Pharmaceutical Co., Ltd. a wholly-owned subsidiary. Despite these challenges, Shionogi revised its FY 2025 forecast, indicating a cautious yet optimistic outlook for the remainder of the fiscal year.
The most recent analyst rating on (JP:4507) stock is a Buy with a Yen2770.00 price target. To see the full list of analyst forecasts on Shionogi & Co stock, see the JP:4507 Stock Forecast page.
More about Shionogi & Co
Shionogi & Co., Ltd. operates in the pharmaceutical industry, focusing on the development and distribution of prescription drugs, over-the-counter medications, and quasi-drugs. The company has a significant presence in the treatment of acute respiratory viral infections, including COVID-19 and influenza, and maintains a strong position in the HIV drug market through its royalty income.
YTD Price Performance: 13.08%
Average Trading Volume: 2,301,334
Technical Sentiment Signal: Buy
Current Market Cap: Yen2148.7B
Find detailed analytics on 4507 stock on TipRanks’ Stock Analysis page.